ATROPINE SULFATE (atropine sulfate monohydrate) by Somerset is (and sympathetic) acetylcholine muscarinic receptors. First approved in 2024.
Drug data last refreshed 19h ago
(and sympathetic) acetylcholine muscarinic receptors. Topical atropine on the eye induces mydriasis by inhibiting contraction of the circular pupillary sphincter muscle normally stimulated by acetylcholine. This inhibition allows the countering radial pupillary dilator muscle to contract which…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of Atropine Sulfate in Healthy Chinese Volunteers
A Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops
A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops
Worked on ATROPINE SULFATE at Somerset? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo